Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

2 weeks ago 14

Jonathan Ponciano, The Motley Fool

Sun, February 22, 2026 astatine 1:36 PM CST 4 min read

On February 17, 2026, Perceptive Advisors disclosed a important bargain of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX), with an estimated transaction worth of $80.34 cardinal based connected quarterly mean pricing, according to its latest SEC filing.

According to a February 17, 2026, SEC filing, Perceptive Advisors LLC accrued its involvement successful Praxis Precision Medicines (NASDAQ:PRAX) by 431,432 shares during the 4th fourth of 2025. The estimated worth of this commercialized was astir $80.34 million, calculated utilizing the mean unadjusted adjacent terms for the period. The quarter-end worth of the presumption accrued by $505.38 million, reflecting some the stock acquisition and consequent banal terms movement.

Top 5 holdings aft the filing:
- NASDAQ:PRAX: $588.30 cardinal (10.8% of AUM)
- NASDAQ:CELC: $315.20 cardinal (5.8% of AUM)
- NASDAQ:RYTM: $272.57 cardinal (5.0% of AUM)
- NASDAQ:ASND: $230.60 cardinal (4.2% of AUM)
- NASDAQ:APGE: $175.92 cardinal (3.2% of AUM)
As of February 17, 2026, Praxis Precision Medicines shares were priced astatine $328.04, up a steep 320% implicit the anterior year.

Metric

Value

Price (as of marketplace adjacent February 17, 2026)	$328.04
Revenue (TTM)	$7.46 million
Net income (TTM)	($273.04 million)

Praxis Precision Medicines develops clinical-stage therapies for cardinal tense strategy disorders, with a pipeline including PRAX-114 for large depressive upset and PRAX-944 for indispensable tremor
The steadfast operates a biopharmaceutical concern exemplary focused connected research, objective development, and out-licensing oregon commercialization of proprietary cause candidates
It targets healthcare providers, specialists successful neurology and psychiatry, and patients with neurological and psychiatric conditions

Praxis Precision Medicines is simply a Boston-based biotechnology institution specializing successful the improvement of caller therapies for disorders characterized by neuronal imbalance. With a focused pipeline addressing large depressive disorder, indispensable tremor, and uncommon epilepsies, the institution leverages proprietary probe and strategical collaborations to beforehand its candidates done objective stages. Praxis differentiates itself done its accent connected precision medicine and targeted cardinal tense strategy treatments, aiming to code unmet aesculapian needs successful neurology and psychiatry.

When a biotech crosses from pipeline communicative to pending commercialized launch, portfolio weightings thin to alteration fast, and that is precisely what is happening here.

Praxis has present submitted 2 NDAs to the FDA, 1 for ulixacaltamide successful indispensable tremor and the different for relutrigine successful SCN2A and SCN8A DEEs. Management is openly preparing for commercialization and scaling inventory up of imaginable approvals. The institution ended 2025 with $926 cardinal successful currency and investments and added $621 cardinal successful January financing, extending its runway into 2028.

That equilibrium expanse matters. It gives Praxis flexibility to motorboat without instantly returning to superior markets. Meanwhile, probe and improvement spending climbed to $267 cardinal for 2025, reflecting a late-stage propulsion crossed aggregate programs.

At 11% of assets, this is the largest disclosed holding. It sits good up of Celcuity and Rhythm, reinforcing a penchant for CNS and specialty biotech with near-term catalysts. Long-term investors should absorption little connected the 320% one-year determination and much connected execution risk. Two NDAs, Phase 3 readouts successful 2026, and a defined currency runway make a high-upside setup, but for a steadfast with lofty expectations.

Read Entire Article